Expertise in
53
conditions

Dr. Tondre T. Buck

Hematology
SMc-Center For Hematology Oncology-Union
1201 Furman L Fendley Hwy Ste D, 
Union, SC 
Accepting New Patients
Expertise in
53
conditions
SMc-Center For Hematology Oncology-Union
1201 Furman L Fendley Hwy Ste D, 
Union, SC 

Overview

Tondre Buck is a Hematologist practicing medicine in Union, South Carolina.

Dr. Buck is highly rated in 53 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, Thrombocytopenia, Bone Marrow Aspiration, and Bone Marrow Transplant.

He is actively involved in clinical research, co-authoring 5 peer reviewed articles and participating in 5 clinical trials. Dr. Buck is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in MS

Hospital Affiliations

Prisma Health Greenville Memorial Hospital
Spartanburg Medical Center
Union Medical Center
Pelham Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Absolute Total Care South Carolina
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

SMc-Center For Hematology Oncology-Union
1201 Furman L Fendley Hwy Ste D, Union, SC 29379
Other Locations
SMc-Center For Hematology/Oncology-Spartanburg
380 Serpentine Dr Ste 200, Spartanburg, SC 29303

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide With or Without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)
Enrollment Status: Completed
Publish Date: April 28, 2026
Intervention Type: Drug, Other, Biological
Study Drugs: Bortezomib, Dexamethasone, Elotuzumab, Lenalidomide
Study Phase: Phase 1/Phase 2
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination With BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients With Molecular Evidence of Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 18, 2025
Intervention Type: Drug, Other
Study Drugs: Bosutinib, Dasatinib, Nilotinib, Nilotinib Hydrochloride Monohydrate, Ruxolitinib, Ruxolitinib Phosphate
Study Phase: Phase 2
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients With Multiple Myeloma Relapsing on Lenalidomide as Part of First Line Therapy
Enrollment Status: Unknown
Publish Date: December 01, 2023
Intervention Type: Drug
Study Drugs: Pomalidomide, Ixazomib, Dexamethasone
Study Phase: Phase 1/Phase 2
View 4 Less Clinical Trials

5 Total Publications

Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Review of the first on-body injector (OBI) for the subcutaneous delivery of an oncology drug: isatuximab in multiple myeloma.
Journal: Expert opinion on drug delivery
Published: April 13, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Ruben A. Mesa
Hematology | Oncology
Expertise in
17
conditions
Dr. Ruben A. Mesa
Hematology | Oncology
Referral required
Before you request

Atrium Health Levine Cancer Institute

1021 Morehead Medical Drive, 
Charlotte, NC 
 (56.7 miles away)
980-442-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Mesa is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Transplant, and Splenectomy. Dr. Mesa is board certified in American Board Of Internal Medicine, Hematology. Dr. Mesa is currently accepting new patients.

Expertise in
21
conditions
Dr. Nilanjan Ghosh
Hematology | Oncology
Expertise in
21
conditions
Dr. Nilanjan Ghosh
Hematology | Oncology
Referral may be required
Before you request

Atrium Health Levine Cancer Institute (Hematology)

1021 Morehead Medical Drive, Building 2, Suite 60201, 
Charlotte, NC 
 (56.7 miles away)
980-442-4363
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Nilanjan Ghosh is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Ghosh is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Mantle Cell Lymphoma (MCL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ghosh is currently accepting new patients.

Expertise in
14
conditions
Dr. Peter M. Voorhees
Hematology | Oncology
Expertise in
14
conditions
Dr. Peter M. Voorhees
Hematology | Oncology
Referral required
Before you request

Atrium Health Levine Cancer Institute (Hematology)

1021 Morehead Medical Drive, Building 2, Suite 60201, 
Charlotte, NC 
 (56.7 miles away)
980-442-4363
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Voorhees is a Hematologist and an Oncologist practicing medicine in Charlotte, North Carolina. Dr. Voorhees is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Voorhees is board certified in American Board Of Internal Medicine, Hematology. Dr. Voorhees is currently accepting new patients.

Frequently Asked Questions about Dr. Tondre T. Buck

How do I make an appointment with Dr. Tondre T. Buck?

You can book an appointment with Dr. Tondre T. Buck by calling their office at 864-427-4993. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Tondre T. Buck a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Tondre T. Buck is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Tondre T. Buck specialize in?

While Dr. Tondre T. Buck is a Hematology, they have specific expertise in Multiple Myeloma, Large-Cell Immunoblastic Lymphoma, and Thrombocytopenia. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Tondre T. Buck participate in research or clinical trials?

Yes. Dr. Tondre T. Buck has published 5 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Tondre T. Buck's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Tondre T. Buck accept my insurance?

Dr. Tondre T. Buck accepts most major insurance plans, including Absolute Total Care South Carolina and Aetna. We recommend calling the office directly at 864-427-4993 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Buck's expertise for a condition
ConditionClose
    View All 48 Advanced Conditions
    View All 51 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile